Biogen Idec Inc (BIIB) 414.13 $BIIB Top Funds B
Post# of 64074
Posted On: 03/04/2015 5:59:04 PM
Biogen Idec Inc (BIIB) 414.13 $BIIB
Top Funds Buying Rackspace, Allergan, Biogen Idec, Apple
at Investor's Business Daily - Tue Mar 03, 5:50PM CST
The nation's top-rated mutual funds the past three months have been big buyers of large medical names such as Allergan (AGN) in their latest reporting periods. IBD's biotech/biomedical group was ranked No. 1 among 197 industries as of Tuesday. Others...
AMZN: 382.72 (-1.89), BIIB: 414.13 (+1.34), MNST: 139.54 (-1.15), HD: 114.76 (-1.31), RAX: 50.32 (-0.43), PCYC: 230.48 (+13.72), SPG: 187.56 (-2.05), ORLY: 207.83 (-3.83), SLXP: 157.13 (+0.63), AGN: 235.68 (+0.82), V: 273.75 (-1.55), LNKD: 265.23 (-0.31), GOOGL: 578.33 (-0.46), LOW: 74.02 (-0.99), HBI: 32.32 (-95.63), ULTA: 139.91 (-2.12), CMCSA: 60.43 (+0.47), AAPL: 128.54 (-0.82), MA: 91.71 (+0.74)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 414.13 (+1.34), GILD: 103.06 (+0.27), PFE: 34.64 (+0.08), MRK: 57.88 (-0.46), AMGN: 159.19 (+0.63), ABBV: 60.27 (+0.65), GSK: 47.82 (+0.11), BMY: 65.67 (+3.75), HSP: 87.95 (+0.24), NVS: 99.04 (-0.02), CELG: 119.57 (+1.10)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 382.72 (-1.89), BIIB: 414.13 (+1.34), FB: 80.89 (+1.29), AMGN: 159.19 (+0.63), H: 60.77 (-0.49), INTC: 34.12 (+0.02), PCLN: 1,225.67 (-16.36), CELG: 119.57 (+1.10), SBUX: 93.06 (-0.94), GILD: 103.06 (+0.27), MSFT: 43.06 (-0.22), AAPL: 128.54 (-0.82), CSCO: 29.33 (-0.21), ONNN: 13.02 (+0.15)
Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success, New Report Launched
M2 - Tue Mar 03, 5:18AM CST
Market Research Reports, Inc. has announced the addition of "Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success" research report to their website http://www.MarketResearchReports.com
BIIB: 414.13 (+1.34), AMGN: 159.19 (+0.63)
Big Cap 20 Reflecting Market Leadership
at Investor's Business Daily - Mon Mar 02, 5:44PM CST
The Big Cap 20 is showing itself to be a good representation of today's market leadership, as technology, health care and consumer stocks dominate the list. A glance of the IBD Smart NYSE + Nasdaq Tables shows chips, medical, apparel, retail and...
SBUX: 93.06 (-0.94), CI: 121.86 (+0.75), BIIB: 414.13 (+1.34), VRX: 203.15 (+0.54), QRVO: 72.02 (+1.18), PCYC: 230.48 (+13.72), ORLY: 207.83 (-3.83), UNH: 113.82 (+0.96), ADI: 58.40 (-0.34), MYL: 55.60 (+0.16), AAPL: 128.54 (-0.82), ROST: 105.12 (-0.42)
After Yesterday's Rally of 1.51% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 02, 3:49PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $406.40 to a high of $416.82. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $412.02 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 414.13 (+1.34)
Biogen/Sobi Report Postive Phase III Data on Alprolix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 1:10PM CST
Biogen (BIIB) and Sobi together announced positive results from a phase III study on their hemophilia B drug, Alprolix.
BIIB: 414.13 (+1.34), CBM: 33.97 (+0.02), ISIS: 70.16 (+1.50), THRX: 19.64 (+0.08)
Biogen Idec: A Great Company, But Not An Alpha Opportunity
Lee Taylor - at Seeking Alpha - Mon Mar 02, 11:39AM CST
BIIB: 414.13 (+1.34), SAN: 7.20 (-0.03), ALXN: 182.53 (+0.02), NVS: 99.04 (-0.02)
Brain Injury Therapeutics Pipeline Review 2015 - 5 Companies & 10 Drug Profiles
M2 - Mon Mar 02, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/qgg676/brain_injury) has announced the addition of the "Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Biogen Idec Inc. - Chiesi Farmaceutici SpA - Faron Pharmaceuticals Oy - Virogenomics, Inc. Drug Profiles - Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - interferon beta-1a - Peptide to Inhibit Pannexin-1 for Brain Injury - PRE-084 - Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury - Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury - RTL-551 - Small Molecules to Block TRPC3 for Acute Brain Injury - Small Molecules to Inhibit Caspase-2 for Neonatal Brain Injury - Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury For more information visit http://www.researchandmarkets.com/research/qg...ain_injury
BIIB: 414.13 (+1.34), ACOR: 35.74 (+0.54)
Isis Pharmaceuticals Up on Q4 Earnings and Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 9:40AM CST
Isis Pharmaceuticals (ISIS) reported fourth-quarter 2014 earnings of 25 cents per share, easily beating the Zacks Consensus Estimate of 12 cents per share.
BIIB: 414.13 (+1.34), ISIS: 70.16 (+1.50), GSK: 47.82 (+0.11), THRX: 19.64 (+0.08)
Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 9:24AM CST
JNJ: 101.65 (-0.69), BIIB: 414.13 (+1.34), ACAD: 38.14 (unch), SPY: 210.23 (-0.89), PCYC: 230.48 (+13.72), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), ALXN: 182.53 (+0.02), IBB: 340.09 (+2.17), CELG: 119.57 (+1.10)
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Pipeline Review 2015 - 11 Companies & 15 Drug Profiles
M2 - Mon Mar 02, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/trxjfk/secondary) has announced the addition of the "Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2015" report to their offering. Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2015', provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - AB Science - Biogen Idec Inc. - Daval International Ltd. - Genzyme Corporation - Glialogix, Inc. - Immune Response BioPharma, Inc. - Innate Therapeutics Limited - Kyorin Pharmaceutical Co., Ltd. - MedDay - Novartis AG - Opexa Therapeutics, Inc. Drug Profiles - Aimspro - BIIB-033 - DC-TAB - GLX-1112 - GZ-402668 - ibudilast - imilecleucel-t - interferon beta-1b - IR-902 - masitinib - MD-1003 - MIS-416 - natalizumab - siponimod - Small Molecules for Multiple Sclerosis For more information visit http://www.researchandmarkets.com/research/trxjfk/secondary
BIIB: 414.13 (+1.34), OPXA: 0.87 (-0.04), NVS: 99.04 (-0.02)
Novo Nordisk, Takeda, Servier, Celgene Among Top Sponsors Rated by Investigative Sites in New CenterWatch Survey
Business Wire - Mon Mar 02, 7:00AM CST
More than 1,900 global investigative sites rate the best biopharmaceutical companies with which to work in a new survey conducted by CenterWatch, a leading provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
BIIB: 414.13 (+1.34), NVO: 47.05 (-0.17), CELGZ: 3.24 (+0.01)
Why Don't These Winning Stocks Pay Dividends?
Dan Caplinger, The Motley Fool - Motley Fool - Sun Mar 01, 4:03PM CST
Warren Buffett loves dividend-paying stocks, but his company isn't going to become one. The majority of companies in the S&P 500 pay dividends. Yet when you look at the upper ranks of the illustrious index, you'll find that several of its...
BIIB: 414.13 (+1.34), AMZN: 382.72 (-1.89), GILD: 103.06 (+0.27), GOOG: 573.37 (-0.27)
3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 01, 6:12AM CST
Source: Celgene Corporation Gilead Sciences ' blockbuster launches of the hepatitis C drugs Sovaldi and Harvoni resulted in its revenue jumping 122% in 2014, but with Gilead Sciences facing tough comparisons this year, these three big-cap biotech...
JNJ: 101.65 (-0.69), BIIB: 414.13 (+1.34), PCYC: 230.48 (+13.72), GILD: 103.06 (+0.27), CELG: 119.57 (+1.10)
Some Companies Are More Wonderful Than Others
Investing Doc - at Seeking Alpha - Sun Mar 01, 4:02AM CST
BBT: 37.81 (-0.36), MON: 119.86 (-0.34), EA: 57.20 (+0.53), HSY: 101.53 (-1.02), ED: 61.87 (-0.30), SYY: 38.81 (-0.09), LM: 57.00 (-0.92), INTC: 34.12 (+0.02), UPS: 100.42 (-1.08), PGR: 26.42 (-0.37), BSX: 16.79 (+0.03), SPY: 210.23 (-0.89), JPM: 62.13 (+0.16), COF: 78.65 (-0.49), FII: 33.73 (+0.21), DE: 90.45 (-0.82), LOW: 74.02 (-0.99), MSFT: 43.06 (-0.22), ROK: 114.85 (-2.28), CSCO: 29.33 (-0.21), MA: 91.71 (+0.74), SYK: 92.37 (-0.07), BCS: 16.03 (+0.37), BCR: 167.66 (+0.48), ISCA: 31.59 (+0.05), RNR: 100.54 (-1.51), PFE: 34.64 (+0.08), WFC: 54.82 (-0.63), MO: 55.79 (-0.67), ISRG: 500.56 (-8.51), CPB: 46.31 (-0.64), SHW: 285.91 (-0.02), CVX: 105.16 (unch), INTU: 97.45 (-0.55), ADSK: 62.52 (-0.18), NVS: 99.04 (-0.02), GD: 136.25 (-0.84), MMM: 167.16 (-1.11), BDX: 148.36 (+2.10), GE: 25.66 (-0.20), CHRW: 73.96 (-0.71), CLX: 109.93 (-0.91), MDT: 78.19 (+0.16), BLK: 369.14 (-4.52), KMB: 108.37 (-1.89), C: 53.67 (-0.06), KEY: 13.90 (-0.10), MMC: 56.45 (-0.56), JNJ: 101.65 (-0.69), CME: 96.49 (-0.61), CINF: 52.37 (-0.43), PPG: 235.34 (+0.80), BMO: 61.32 (+0.29), FITB: 19.28 (-0.21), HD: 114.76 (-1.31), WU: 19.65 (-0.07), GGG: 75.70 (-1.28), EMR: 57.78 (-0.60), BMY: 65.67 (+3.75), CTAS: 83.77 (-0.44), JOE: 16.85 (-0.20), USB: 44.41 (-0.34), PG: 84.35 (-0.81), IGT: 17.96 (-0.03), BEN: 53.33 (-0.51), CMCSA: 60.43 (+0.47), MXIM: 35.39 (+0.30), RF: 9.55 (-0.07), MKC: 74.84 (-0.41), UTX: 121.04 (-0.66), MTB: 122.45 (-0.28), WMT: 82.58 (-0.79), GOOG: 573.37 (-0.27), SLB: 85.14 (+0.23), SLM: 9.46 (-0.09), TGT: 77.72 (-0.28), LYG: 4.88 (-0.04), FWRD: 52.77 (-0.31), CLMS: 12.62 (+0.22), STR: 23.04 (-0.19), AVP: 9.10 (+0.28), STT: 75.13 (-0.24), VFC: 76.49 (-0.20), LLTC: 47.55 (-0.65), IRM: 36.49 (-0.90), MHFI: 102.55 (-1.07), FDO: 78.59 (-0.07), GSK: 47.82 (+0.11), TIF: 86.79 (-2.15), ADP: 86.57 (-2.13), WBA: 83.02 (-0.19), SIAL: 138.13 (-0.07), MRK: 57.88 (-0.46), EXPD: 47.99 (-0.09), MCD: 100.25 (+0.51), DOV: 71.63 (-0.50), BRK.B: 144.92 (-1.01), WTW: 9.97 (-0.62), CTL: 36.25 (-1.43), BIIB: 414.13 (+1.34), LMT: 198.97 (-0.96), XOM: 87.18 (-0.44), PEP: 97.36 (-1.04), TWX: 83.08 (-0.08), SWK: 97.32 (-1.06), SBUX: 93.06 (-0.94), PAYX: 48.79 (-0.54), FAST: 39.82 (-1.28), EBAY: 58.31 (+0.05), QCOM: 70.84 (-0.56), DIA: 180.78 (-1.09), SNV: 27.34 (-0.13), AVY: 53.23 (-0.03), SNY: 48.34 (+0.26), BK: 39.44 (-0.21), HRB: 33.42 (-0.29), KO: 42.50 (-0.45), AXP: 80.63 (-1.28), SVU: 10.18 (+0.28), NUE: 47.41 (+0.26), LEG: 45.37 (-0.38), AMGN: 159.19 (+0.63), DIS: 105.57 (-0.78), BAC: 15.84 (-0.20), ORCL: 43.61 (+0.23), BRO: 31.75 (-0.17), JCI: 50.70 (-0.75), CL: 70.68 (unch)
How To Invest: Avoid Bases Of Low-Priced Stocks
at Investor's Business Daily - Fri Feb 27, 4:44PM CST
Many investors are drawn to low-priced stocks like bears to honey. Truth is, it's an area of the market where institutional investors rarely fish. That means you shouldn't fish there, either. Prior to today, seven columns in this space have addressed...
BIIB: 414.13 (+1.34), LNKD: 265.23 (-0.31), MHK: 185.03 (-0.56), CMG: 664.16 (-4.27), SHW: 285.91 (-0.02), MA: 91.71 (+0.74)
Biogen's hemophilia B med successful in Phase 3 trial in children
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 8:59AM CST
BIIB: 414.13 (+1.34), ALNY: 107.23 (+0.32), OPK: 14.37 (-0.03), ONCE: 54.53 (-0.47), BAX: 69.25 (-0.17), SHPG: 239.64 (+0.74), PFE: 34.64 (+0.08), SGMO: 17.98 (+0.90)
Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences
at The Street - Fri Feb 27, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 414.13 (+1.34), CLDX: 29.30 (+2.93), RCPT: 128.00 (+3.01), EXAS: 21.90 (+0.84)
Top Funds Buying Rackspace, Allergan, Biogen Idec, Apple
at Investor's Business Daily - Tue Mar 03, 5:50PM CST
The nation's top-rated mutual funds the past three months have been big buyers of large medical names such as Allergan (AGN) in their latest reporting periods. IBD's biotech/biomedical group was ranked No. 1 among 197 industries as of Tuesday. Others...
AMZN: 382.72 (-1.89), BIIB: 414.13 (+1.34), MNST: 139.54 (-1.15), HD: 114.76 (-1.31), RAX: 50.32 (-0.43), PCYC: 230.48 (+13.72), SPG: 187.56 (-2.05), ORLY: 207.83 (-3.83), SLXP: 157.13 (+0.63), AGN: 235.68 (+0.82), V: 273.75 (-1.55), LNKD: 265.23 (-0.31), GOOGL: 578.33 (-0.46), LOW: 74.02 (-0.99), HBI: 32.32 (-95.63), ULTA: 139.91 (-2.12), CMCSA: 60.43 (+0.47), AAPL: 128.54 (-0.82), MA: 91.71 (+0.74)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 414.13 (+1.34), GILD: 103.06 (+0.27), PFE: 34.64 (+0.08), MRK: 57.88 (-0.46), AMGN: 159.19 (+0.63), ABBV: 60.27 (+0.65), GSK: 47.82 (+0.11), BMY: 65.67 (+3.75), HSP: 87.95 (+0.24), NVS: 99.04 (-0.02), CELG: 119.57 (+1.10)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 382.72 (-1.89), BIIB: 414.13 (+1.34), FB: 80.89 (+1.29), AMGN: 159.19 (+0.63), H: 60.77 (-0.49), INTC: 34.12 (+0.02), PCLN: 1,225.67 (-16.36), CELG: 119.57 (+1.10), SBUX: 93.06 (-0.94), GILD: 103.06 (+0.27), MSFT: 43.06 (-0.22), AAPL: 128.54 (-0.82), CSCO: 29.33 (-0.21), ONNN: 13.02 (+0.15)
Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success, New Report Launched
M2 - Tue Mar 03, 5:18AM CST
Market Research Reports, Inc. has announced the addition of "Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success" research report to their website http://www.MarketResearchReports.com
BIIB: 414.13 (+1.34), AMGN: 159.19 (+0.63)
Big Cap 20 Reflecting Market Leadership
at Investor's Business Daily - Mon Mar 02, 5:44PM CST
The Big Cap 20 is showing itself to be a good representation of today's market leadership, as technology, health care and consumer stocks dominate the list. A glance of the IBD Smart NYSE + Nasdaq Tables shows chips, medical, apparel, retail and...
SBUX: 93.06 (-0.94), CI: 121.86 (+0.75), BIIB: 414.13 (+1.34), VRX: 203.15 (+0.54), QRVO: 72.02 (+1.18), PCYC: 230.48 (+13.72), ORLY: 207.83 (-3.83), UNH: 113.82 (+0.96), ADI: 58.40 (-0.34), MYL: 55.60 (+0.16), AAPL: 128.54 (-0.82), ROST: 105.12 (-0.42)
After Yesterday's Rally of 1.51% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 02, 3:49PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $406.40 to a high of $416.82. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $412.02 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 414.13 (+1.34)
Biogen/Sobi Report Postive Phase III Data on Alprolix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 1:10PM CST
Biogen (BIIB) and Sobi together announced positive results from a phase III study on their hemophilia B drug, Alprolix.
BIIB: 414.13 (+1.34), CBM: 33.97 (+0.02), ISIS: 70.16 (+1.50), THRX: 19.64 (+0.08)
Biogen Idec: A Great Company, But Not An Alpha Opportunity
Lee Taylor - at Seeking Alpha - Mon Mar 02, 11:39AM CST
BIIB: 414.13 (+1.34), SAN: 7.20 (-0.03), ALXN: 182.53 (+0.02), NVS: 99.04 (-0.02)
Brain Injury Therapeutics Pipeline Review 2015 - 5 Companies & 10 Drug Profiles
M2 - Mon Mar 02, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/qgg676/brain_injury) has announced the addition of the "Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Biogen Idec Inc. - Chiesi Farmaceutici SpA - Faron Pharmaceuticals Oy - Virogenomics, Inc. Drug Profiles - Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - interferon beta-1a - Peptide to Inhibit Pannexin-1 for Brain Injury - PRE-084 - Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury - Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury - RTL-551 - Small Molecules to Block TRPC3 for Acute Brain Injury - Small Molecules to Inhibit Caspase-2 for Neonatal Brain Injury - Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury For more information visit http://www.researchandmarkets.com/research/qg...ain_injury
BIIB: 414.13 (+1.34), ACOR: 35.74 (+0.54)
Isis Pharmaceuticals Up on Q4 Earnings and Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 9:40AM CST
Isis Pharmaceuticals (ISIS) reported fourth-quarter 2014 earnings of 25 cents per share, easily beating the Zacks Consensus Estimate of 12 cents per share.
BIIB: 414.13 (+1.34), ISIS: 70.16 (+1.50), GSK: 47.82 (+0.11), THRX: 19.64 (+0.08)
Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 9:24AM CST
JNJ: 101.65 (-0.69), BIIB: 414.13 (+1.34), ACAD: 38.14 (unch), SPY: 210.23 (-0.89), PCYC: 230.48 (+13.72), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), ALXN: 182.53 (+0.02), IBB: 340.09 (+2.17), CELG: 119.57 (+1.10)
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Pipeline Review 2015 - 11 Companies & 15 Drug Profiles
M2 - Mon Mar 02, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/trxjfk/secondary) has announced the addition of the "Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2015" report to their offering. Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2015', provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - AB Science - Biogen Idec Inc. - Daval International Ltd. - Genzyme Corporation - Glialogix, Inc. - Immune Response BioPharma, Inc. - Innate Therapeutics Limited - Kyorin Pharmaceutical Co., Ltd. - MedDay - Novartis AG - Opexa Therapeutics, Inc. Drug Profiles - Aimspro - BIIB-033 - DC-TAB - GLX-1112 - GZ-402668 - ibudilast - imilecleucel-t - interferon beta-1b - IR-902 - masitinib - MD-1003 - MIS-416 - natalizumab - siponimod - Small Molecules for Multiple Sclerosis For more information visit http://www.researchandmarkets.com/research/trxjfk/secondary
BIIB: 414.13 (+1.34), OPXA: 0.87 (-0.04), NVS: 99.04 (-0.02)
Novo Nordisk, Takeda, Servier, Celgene Among Top Sponsors Rated by Investigative Sites in New CenterWatch Survey
Business Wire - Mon Mar 02, 7:00AM CST
More than 1,900 global investigative sites rate the best biopharmaceutical companies with which to work in a new survey conducted by CenterWatch, a leading provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
BIIB: 414.13 (+1.34), NVO: 47.05 (-0.17), CELGZ: 3.24 (+0.01)
Why Don't These Winning Stocks Pay Dividends?
Dan Caplinger, The Motley Fool - Motley Fool - Sun Mar 01, 4:03PM CST
Warren Buffett loves dividend-paying stocks, but his company isn't going to become one. The majority of companies in the S&P 500 pay dividends. Yet when you look at the upper ranks of the illustrious index, you'll find that several of its...
BIIB: 414.13 (+1.34), AMZN: 382.72 (-1.89), GILD: 103.06 (+0.27), GOOG: 573.37 (-0.27)
3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 01, 6:12AM CST
Source: Celgene Corporation Gilead Sciences ' blockbuster launches of the hepatitis C drugs Sovaldi and Harvoni resulted in its revenue jumping 122% in 2014, but with Gilead Sciences facing tough comparisons this year, these three big-cap biotech...
JNJ: 101.65 (-0.69), BIIB: 414.13 (+1.34), PCYC: 230.48 (+13.72), GILD: 103.06 (+0.27), CELG: 119.57 (+1.10)
Some Companies Are More Wonderful Than Others
Investing Doc - at Seeking Alpha - Sun Mar 01, 4:02AM CST
BBT: 37.81 (-0.36), MON: 119.86 (-0.34), EA: 57.20 (+0.53), HSY: 101.53 (-1.02), ED: 61.87 (-0.30), SYY: 38.81 (-0.09), LM: 57.00 (-0.92), INTC: 34.12 (+0.02), UPS: 100.42 (-1.08), PGR: 26.42 (-0.37), BSX: 16.79 (+0.03), SPY: 210.23 (-0.89), JPM: 62.13 (+0.16), COF: 78.65 (-0.49), FII: 33.73 (+0.21), DE: 90.45 (-0.82), LOW: 74.02 (-0.99), MSFT: 43.06 (-0.22), ROK: 114.85 (-2.28), CSCO: 29.33 (-0.21), MA: 91.71 (+0.74), SYK: 92.37 (-0.07), BCS: 16.03 (+0.37), BCR: 167.66 (+0.48), ISCA: 31.59 (+0.05), RNR: 100.54 (-1.51), PFE: 34.64 (+0.08), WFC: 54.82 (-0.63), MO: 55.79 (-0.67), ISRG: 500.56 (-8.51), CPB: 46.31 (-0.64), SHW: 285.91 (-0.02), CVX: 105.16 (unch), INTU: 97.45 (-0.55), ADSK: 62.52 (-0.18), NVS: 99.04 (-0.02), GD: 136.25 (-0.84), MMM: 167.16 (-1.11), BDX: 148.36 (+2.10), GE: 25.66 (-0.20), CHRW: 73.96 (-0.71), CLX: 109.93 (-0.91), MDT: 78.19 (+0.16), BLK: 369.14 (-4.52), KMB: 108.37 (-1.89), C: 53.67 (-0.06), KEY: 13.90 (-0.10), MMC: 56.45 (-0.56), JNJ: 101.65 (-0.69), CME: 96.49 (-0.61), CINF: 52.37 (-0.43), PPG: 235.34 (+0.80), BMO: 61.32 (+0.29), FITB: 19.28 (-0.21), HD: 114.76 (-1.31), WU: 19.65 (-0.07), GGG: 75.70 (-1.28), EMR: 57.78 (-0.60), BMY: 65.67 (+3.75), CTAS: 83.77 (-0.44), JOE: 16.85 (-0.20), USB: 44.41 (-0.34), PG: 84.35 (-0.81), IGT: 17.96 (-0.03), BEN: 53.33 (-0.51), CMCSA: 60.43 (+0.47), MXIM: 35.39 (+0.30), RF: 9.55 (-0.07), MKC: 74.84 (-0.41), UTX: 121.04 (-0.66), MTB: 122.45 (-0.28), WMT: 82.58 (-0.79), GOOG: 573.37 (-0.27), SLB: 85.14 (+0.23), SLM: 9.46 (-0.09), TGT: 77.72 (-0.28), LYG: 4.88 (-0.04), FWRD: 52.77 (-0.31), CLMS: 12.62 (+0.22), STR: 23.04 (-0.19), AVP: 9.10 (+0.28), STT: 75.13 (-0.24), VFC: 76.49 (-0.20), LLTC: 47.55 (-0.65), IRM: 36.49 (-0.90), MHFI: 102.55 (-1.07), FDO: 78.59 (-0.07), GSK: 47.82 (+0.11), TIF: 86.79 (-2.15), ADP: 86.57 (-2.13), WBA: 83.02 (-0.19), SIAL: 138.13 (-0.07), MRK: 57.88 (-0.46), EXPD: 47.99 (-0.09), MCD: 100.25 (+0.51), DOV: 71.63 (-0.50), BRK.B: 144.92 (-1.01), WTW: 9.97 (-0.62), CTL: 36.25 (-1.43), BIIB: 414.13 (+1.34), LMT: 198.97 (-0.96), XOM: 87.18 (-0.44), PEP: 97.36 (-1.04), TWX: 83.08 (-0.08), SWK: 97.32 (-1.06), SBUX: 93.06 (-0.94), PAYX: 48.79 (-0.54), FAST: 39.82 (-1.28), EBAY: 58.31 (+0.05), QCOM: 70.84 (-0.56), DIA: 180.78 (-1.09), SNV: 27.34 (-0.13), AVY: 53.23 (-0.03), SNY: 48.34 (+0.26), BK: 39.44 (-0.21), HRB: 33.42 (-0.29), KO: 42.50 (-0.45), AXP: 80.63 (-1.28), SVU: 10.18 (+0.28), NUE: 47.41 (+0.26), LEG: 45.37 (-0.38), AMGN: 159.19 (+0.63), DIS: 105.57 (-0.78), BAC: 15.84 (-0.20), ORCL: 43.61 (+0.23), BRO: 31.75 (-0.17), JCI: 50.70 (-0.75), CL: 70.68 (unch)
How To Invest: Avoid Bases Of Low-Priced Stocks
at Investor's Business Daily - Fri Feb 27, 4:44PM CST
Many investors are drawn to low-priced stocks like bears to honey. Truth is, it's an area of the market where institutional investors rarely fish. That means you shouldn't fish there, either. Prior to today, seven columns in this space have addressed...
BIIB: 414.13 (+1.34), LNKD: 265.23 (-0.31), MHK: 185.03 (-0.56), CMG: 664.16 (-4.27), SHW: 285.91 (-0.02), MA: 91.71 (+0.74)
Biogen's hemophilia B med successful in Phase 3 trial in children
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 8:59AM CST
BIIB: 414.13 (+1.34), ALNY: 107.23 (+0.32), OPK: 14.37 (-0.03), ONCE: 54.53 (-0.47), BAX: 69.25 (-0.17), SHPG: 239.64 (+0.74), PFE: 34.64 (+0.08), SGMO: 17.98 (+0.90)
Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences
at The Street - Fri Feb 27, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 414.13 (+1.34), CLDX: 29.30 (+2.93), RCPT: 128.00 (+3.01), EXAS: 21.90 (+0.84)
(0)
(0)Scroll down for more posts ▼